Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1G93A) of ALS.

ABSTRACT: BACKGROUND:The development of new therapeutic strategies to treat amyotrophic lateral sclerosis (ALS) is of utmost importance. The use of cyclic nitroxides such as tempol may provide neuroprotection and improve lifespan. We investigated whether tempol (50 mg/kg) presents therapeutic potential in SOD1G93A transgenic mice. METHODS:Tempol treatment began at the asymptomatic phase of the disease (10th week) and was administered every other day until week 14, after which it was administered twice a week until the final stage of the disease. The animals were sacrificed at week 14 (initial stage of symptoms-ISS) and at the end stage (ES) of the disease. The lumbar spinal cord of the animals was dissected and processed for use in the following techniques: Nissl staining to evaluate neuronal surviv

SUBMITTER: Chiarotto GB 

PROVIDER: S-EPMC6857328 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature